Overexpression of CDHR2 inhibits proliferation of breast cancer cells by inhibiting the PI3K/Akt pathway

doi:10.12122/j.issn.1673-4254.2024.06.12

Abstract

Abstract:

Objective To investigate the mechanism by which CDHR2 overexpression inhibits breast cancer cell growth and cell cycle pragression via the PI3K/Akt signaling pathway. Methods Bioinformatic analysis was performed to investigate CDHR2 expression in breast cancer and its correlation with survival outcomes of the patients. Immunohistochemistry was used to examine CDHR2 expressions in surgical specimens of tumor and adjacent tissues from 10 patients with breast cancer. CDHR2 expression levels were also detected in 5 breast cancer cell lines and a normal human mammary epithelial cell line using qRT-PCR and Western blotting. Breast cancer cell lines MDA-MB-231 and MCF7 with low CDHR2 expression were transfected with a CDHR2-overexpressing plasmid, and the changes in cell proliferation and cell cycle were evaluated using CCK-8 assay, EdU assay, and cell cycle assay; the changes in expressions of PI3K/Akt signaling pathway and cell cycle pathway proteins were detected with Western blotting. Results Bioinformatic analysis showed low CDHR2 expression level in both breast cancer and adjacent tissues without significant difference between them (P>0.05), but breast cancer patients with a high expression of CDHR2 had a more favorable prognosis. Immunohistochemistry, qRT-PCR and Western blotting showed that the expression of CDHR2 was significantly down-regulated in breast cancer tissues and breast cancer cells (P<0.01), and its overexpression strongly inhibited cell proliferation, caused cell cycle arrest, and significantly inhibited PI3K and Akt phosphorylation and the expression of cyclin D1. Conclusion Overexpression of CDHR2 inhibits proliferation and causes cell cycle arrest in breast cancer cells possibly by inhibiting the PI3K/Akt signaling pathway.

Key words: breast cancer, CDHR2, PI3K/Akt pathway, proliferation, cell cycle

Jincun FANG, Liwei LIU, Junhao LIN, Fengsheng CHEN. Overexpression of CDHR2 inhibits proliferation of breast cancer cells by inhibiting the PI3K/Akt pathway[J]. Journal of Southern Medical University, 2024, 44(6): 1117-1125.

Figures/Tables 11

Fig.1 Analysis of CDHR2 expression levels in breast cancer and adjacent tissues based on TCGA dataset.

Fig.2 Survival outcomes of breast cancer patients with low and high CDHR2 expressions. A-D: Relationship between CDHR2 expression and prognosis of the patients with triple-negative (A), luminal A (B), luminal B (C), and Her2-overexpressing (D) breast cancer, respectively.

Fig.3 Fig. 3 Immunohistochemical staining for CDHR2 in clinical specimens of breast cancer tissues (Original magnification: ×400). A: Strong expression of CDHR2 in breast tissues. B: Weak expression of CDHR2 in breast tissues. C: Strong expression of CDHR2 in breast cancer tissues. D: Weak expression of CDHR2 in breast cancer tissues. ****P<0.0001.

Fig.4 CDHR2 mRNA expression levels in breast cancer cell lines and normal human mammary epithelial cells. **P<0.01, ***P<0.001 vs MCF10A.

Fig.5 CDHR2 protein expression levels in breast cancer cell lines and normal human mammary epithelial cells detected by Western blotting. ***P<0.001 vs MCF10A.

Fig.6 CDHR2 mRNA expression in MDA-MB-231 and MCF7 cells transfected with CDHR2-overexpressing plasmids. ***P<0.001.

Fig. 7 CCK-8 cell proliferation assay of the transfected breast cancer cell lines. **P<0.01, ***P<0.001.

Fig.8 EdU proliferation assay of the transfected breast cancer cell lines. **P<0.01.

Fig.9 Flow cytometry for cell cycle analysis of the transfected breast cancer cell lines. **P<0.01.

Fig.10 Western blotting of PI3K/Akt signaling pathway proteins and cyclin D1 in the transfected cells. ***P<0.001, ****P<0.0001 vs negetive control (NC).

Fig.11 Proteins with possible binding sites for CDHR2.

References 30

1	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
2	Kawiak A. Molecular research and treatment of breast cancer[J]. Int J Mol Sci, 2022, 23(17): 9617.
3	An JS, Peng C, Tang HL, et al. New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer[J]. Int J Mol Sci, 2021, 22(17): 9644.
4	Barzaman K, Karami J, Zarei Z, et al. Breast cancer: biology, biomarkers, and treatments[J]. Int Immunopharmacol, 2020, 84: 106535.
5	Pancho A, Aerts T, Mitsogiannis MD, et al. Protocadherins at the crossroad of signaling pathways[J]. Front Mol Neurosci, 2020, 13: 117.
6	Yu JS, Koujak S, Nagase S, et al. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer[J]. Oncogene, 2008, 27(34): 4657-65.
7	Harada H, Miyamoto K, Yamashita Y, et al. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer[J]. Cancer Med, 2015, 4(10): 1536-46.
8	Haruki S, Imoto I, Kozaki KI, et al. Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma[J]. Carcinogenesis, 2010, 31(6): 1027-36.
9	Fang S, Huang SF, Cao J, et al. Silencing of PCDH10 in hepatocellular carcinoma via de novo DNA methylation independent of HBV infection or HBX expression[J]. Clin Exp Med, 2013, 13(2): 127-34.
10	Lei SY, Zheng RS, Zhang SW, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020[J]. Cancer Commun, 2021, 41(11): 1183-94.
11	Chodosh LA. Breast cancer: current state and future promise[J]. Breast Cancer Res, 2011, 13(6): 113.
12	McDonald ES, Clark AS, Tchou J, et al. Clinical diagnosis and management of breast cancer[J]. J Nucl Med, 2016, 57(): 9S-16S.
13	Griguolo G, Pascual T, Dieci MV, et al. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer[J]. J Immunother Cancer, 2019, 7(1): 90.
14	Vega-Benedetti AF, Loi E, Moi L, et al. Clustered protocadherins methylation alterations in cancer[J]. Clin Epigenetics, 2019, 11(1): 100.
15	Imoto I, Izumi H, Yokoi S, et al. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers[J]. Cancer Res, 2006, 66(9): 4617-26.
16	Wang CL, Yu GZ, Liu JC, et al. Downregulation of PCDH9 predicts prognosis for patients with glioma[J]. J Clin Neurosci, 2012, 19(4): 541-5.
17	Zhen YL, Pavez M, Li XY. The role of Pcdh10 in neurological disease and cancer[J]. J Cancer Res Clin Oncol, 2023, 149(10): 8153-64.
18	Xia ZY, Huang MJ, Zhu QQ, et al. Cadherin related family member 2 acts As A tumor suppressor by inactivating AKT in human hepatocellular carcinoma[J]. J Cancer, 2019, 10(4): 864-73.
19	Okazaki N, Takahashi N, Kojima SI, et al. Protocadherin LKC, a new candidate for a tumor suppressor of colon and liver cancers, its association with contact inhibition of cell proliferation[J]. Carcinogenesis, 2002, 23(7): 1139-48.
20	Ose R, Yanagawa T, Ikeda S, et al. PCDH24-induced contact inhibition involves downregulation of beta-catenin signaling[J]. Mol Oncol, 2009, 3(1): 54-66.
21	Luo J, Yao JF, Deng XF, et al. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling[J]. J Exp Clin Cancer Res, 2018, 37(1): 23.
22	Spangle JM, Dreijerink KM, Groner AC, et al. PI3K/AKT signaling regulates H3K4 methylation in breast cancer[J]. Cell Rep, 2016, 15(12): 2692-704.
23	Xu JC, Chen TY, Liao LT, et al. NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K/AKT and ERK pathway[J]. Int J Biol Sci, 2021, 17(1): 259-70.
24	Wang Q, He GP, Hou MM, et al. Cell cycle regulation by alternative polyadenylation of CCND1[J]. Sci Rep, 2018, 8(1): 6824.
25	Hermosilla VE, Salgado G, Riffo E, et al. SALL2 represses cyclins D1 and E1 expression and restrains G1/S cell cycle transition and cancer-related phenotypes[J]. Mol Oncol, 2018, 12(7): 1026-46.
26	Feng YF, Qian WW, Zhang Y, et al. CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo [J]. BMC Cancer, 2019, 19(1): 576.
27	Xie ZZ, Li W, Ai JG, et al. C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K/AKT/mTOR signaling pathway[J]. J Transl Med, 2022, 20(1): 264.
28	Zhong Y, Yang LT, Xiong F, et al. Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc[J]. Signal Transduct Target Ther, 2021, 6(1): 240.
29	Kar G, Gursoy A, Keskin O. Human cancer protein-protein interaction network: a structural perspective[J]. PLoS Comput Biol, 2009, 5(12): e1000601.
30	Cho HJ, Hwang YS, Yoon J, et al. EphrinB1 promotes cancer cell migration and invasion through the interaction with RhoGDI1[J]. Oncogene, 2018, 37(7): 861-72.

[1]	Ting XIE, Yunyun WANG, Ting GUO, Chunhua YUAN. The peptide toxin components and nucleotide metabolites in Macrothele raveni venom synergistically inhibit cancer cell proliferation by activating the pro-apoptotic pathways [J]. Journal of Southern Medical University, 2025, 45(7): 1460-1470.
[2]	Jiahao LI, Ruiting XIAN, Rong LI. Down-regulation of ACADM-mediated lipotoxicity inhibits invasion and metastasis of estrogen receptor-positive breast cancer cells [J]. Journal of Southern Medical University, 2025, 45(6): 1163-1173.
[3]	Yumei ZENG, Jike LI, Zhongxi HUANG, Yibo ZHOU. Villin-like protein VILL suppresses proliferation of nasopharyngeal carcinoma cells by interacting with LMO7 protein [J]. Journal of Southern Medical University, 2025, 45(5): 954-961.
[4]	Yaqing YUE, Zhaoxia MU, Xibo WANG, Yan LIU. Aurora-A overexpression promotes cervical cancer cell invasion and metastasis by activating the NF-κBp65/ARPC4 signaling axis [J]. Journal of Southern Medical University, 2025, 45(4): 837-843.
[5]	Yi ZHANG, Yu SHEN, Zhiqiang WAN, Song TAO, Yakui LIU, Shuanhu WANG. High expression of CDKN3 promotes migration and invasion of gastric cancer cells by regulating the p53/NF-κB signaling pathway and inhibiting cell apoptosis [J]. Journal of Southern Medical University, 2025, 45(4): 853-861.
[6]	Shunjie QING, Zhiyong SHEN. High expression of hexokinase 2 promotes proliferation, migration and invasion of colorectal cancer cells by activating the JAK/STAT pathway and regulating tumor immune microenvironment [J]. Journal of Southern Medical University, 2025, 45(3): 542-553.
[7]	Qingqing HUANG, Wenjing ZHANG, Xiaofeng ZHANG, Lian WANG, Xue SONG, Zhijun GENG, Lugen ZUO, Yueyue WANG, Jing LI, Jianguo HU. High MYO1B expression promotes proliferation, migration and invasion of gastric cancer cells and is associated with poor patient prognosis [J]. Journal of Southern Medical University, 2025, 45(3): 622-631.
[8]	Xue SONG, Yue CHEN, Min ZHANG, Nuo ZHANG, Lugen ZUO, Jing LI, Zhijun GENG, Xiaofeng ZHANG, Yueyue WANG, Lian WANG, Jianguo HU. GPSM2 is highly expressed in gastric cancer to affect patient prognosis by promoting tumor cell proliferation [J]. Journal of Southern Medical University, 2025, 45(2): 229-238.
[9]	Di CHEN, Ying LÜ, Yixin GUO, Yirong ZHANG, Ruixuan WANG, Xiaoruo ZHOU, Yuxin CHEN, Xiaohui WU. Dihydroartemisinin enhances doxorubicin-induced apoptosis of triple negative breast cancer cells by negatively regulating the STAT3/HIF-1α pathway [J]. Journal of Southern Medical University, 2025, 45(2): 254-260.
[10]	Jinhua ZOU, Hui WANG, Dongyan ZHANG. SLC1A5 overexpression accelerates progression of hepatocellular carcinoma by promoting M2 polarization of macrophages [J]. Journal of Southern Medical University, 2025, 45(2): 269-284.
[11]	Yu BIN, Ziwen LI, Suwei ZUO, Sinuo SUN, Min LI, Jiayin SONG, Xu LIN, Gang XUE, Jingfang WU. High expression of apolipoprotein C1 promotes proliferation and inhibits apoptosis of papillary thyroid carcinoma cells by activating the JAK2/STAT3 signaling pathway [J]. Journal of Southern Medical University, 2025, 45(2): 359-370.
[12]	Zhoufang CAO, Yuan WANG, Mengna WANG, Yue SUN, Feifei LIU. LINC00837/miR-671-5p/SERPINE2 functional axis promotes pathological processes of fibroblast-like synovial cells in rheumatoid arthritis [J]. Journal of Southern Medical University, 2025, 45(2): 371-378.
[13]	Qiao CHU, Xiaona WANG, Jiaying XU, Huilin PENG, Yulin ZHAO, Jing ZHANG, Guoyu LU, Kai WANG. Pulsatilla saponin D inhibits invasion and metastasis of triple-negative breast cancer cells through multiple targets and pathways [J]. Journal of Southern Medical University, 2025, 45(1): 150-161.
[14]	Xiaohua CHEN, Hui LU, Ziliang WANG, Lian WANG, Yongsheng XIA, Zhijun GENG, Xiaofeng ZHANG, Xue SONG, Yueyue WANG, Jing LI, Jianguo HU, Lugen ZUO. Role of Abelson interactor 2 in progression and prognosis of gastric cancer and its regulatory mechanisms [J]. Journal of Southern Medical University, 2024, 44(9): 1653-1661.
[15]	Liangjun XUE, Qiuyu TAN, Jingwen XU, Lu FENG, Wenjin LI, Liang YAN, Yulei LI. MiR-6838-5p overexpression inhibits proliferation of breast cancer MCF-7 cells by downregulating DDR1 expression [J]. Journal of Southern Medical University, 2024, 44(9): 1677-1684.